Background: Addison’s disease is a rare disorder of the adrenal cortex that leads to inadequate production of cortisol initially followed by aldosterone and androgens. Its manifestations are usually slow and non-specific with potential for life-threatening adrenal crisis following hypermetabolic demands (infection, trauma, surgery). Patients: Over the past 10 years, 19 CRD-patients were diagnosed with occult PAI in our center. Results: Unprovoked hypotension was the most common manifestations of occult PAI and was the unmasking event in 11 (58%). It was without significant cardiac and/or severe systemic sepsis and was refractory to isotonic saline infusions. Equal number of the remaining patients (n = 2) presented with persistent and inexplicable electrolytes abnormalities viz. 1) hyponatremia despite restricted oral fluid intake, lack of dehydration and massive fluid overload, as well as 2) hyperkalemia despite potassium-restricted diet, hyperkalemic drugs and adequate therapy with Furosemide and low-potassium dialysis-baths. On the other hand, similar proportions presented with unprovoked 3) progressive weight loss, decrease appetite and cachexia as well as 4) frequent hypoglycemic attacks. All patients were treated and were medically stable after 29 (2 - 60) months of follow up. Autoantibodies to 21-hydroxylase enzyme were positive in 16 (90%). At diagnosis, and subsequent follow up, only 7 patients (37%) had multi-endocrine dysfunction of whom 2 with type 1 and 5 with type 2. Conclusion: High index of suspicion should be exerted in diagnosis of PAI in patients with CRD, since its clinical picture is similar to CRD manifestations and complications. In those patients, confirmatory tests and specific management can save their lives.
References
[1]
Munir, S., Quintanilla Rodriguez, B.S. and Waseem, M. (2024) Addison Disease. StatPearls.
[2]
Bleicken, B., Ventz, M., Quinkler, M. and Hahner, S. (2010) Delayed Diagnosis of Adrenal Insufficiency Is Common: A Cross-Sectional Study in 216 Patients. The American Journal of the Medical Sciences, 339, 525-531. https://doi.org/10.1097/maj.0b013e3181db6b7a
[3]
Rushworth, R.L., Torpy, D.J. and Falhammar, H. (2016) Adrenal Crises: Perspectives and Research Directions. Endocrine, 55, 336-345. https://doi.org/10.1007/s12020-016-1204-2
[4]
Bancos, I., Hahner, S., Tomlinson, J. and Arlt, W. (2015) Diagnosis and Management of Adrenal Insufficiency. The Lancet Diabetes & Endocrinology, 3, 216-226. https://doi.org/10.1016/s2213-8587(14)70142-1
[5]
Chabre, O., Goichot, B., Zenaty, D. and Bertherat, J. (2017) Group 1. Epidemiology of Primary and Secondary Adrenal Insufficiency: Prevalence and Incidence, Acute Adrenal Insufficiency, Long-Term Morbidity and Mortality. Annales d’Endocrinologie, 78, 490-494. https://doi.org/10.1016/j.ando.2017.10.010
[6]
Javorsky, B.R., Raff, H., Carroll, T.B., Algeciras-Schimnich, A., Singh, R.J., Colón-Franco, J.M., et al. (2021) New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency After ACTH Stimulation Using Specific Cortisol Assays. Journal of the Endocrine Society, 5, bvab022. https://doi.org/10.1210/jendso/bvab022
[7]
Bornstein, S.R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G.D., et al. (2016) Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 101, 364-389. https://doi.org/10.1210/jc.2015-1710
[8]
Addison T. (1855) On the Constitutional and Local Effects of Disease of the Suprarenal Capsule. Wellcome Collections of Electronic Books on Medical Heritage Library, 1-82. https://wellcomecollection.org/works/xsmzqpdw
[9]
Patnaik, M.M. and Deshpande, A.K. (2008) Diagnosis-Addison’s Disease Secondary to Tuberculosis of the Adrenal Glands. Clinical Medicine & Research, 6, 29-29. https://doi.org/10.3121/cmr.2007.754a
[10]
Falorni, A., Nikoshkov, A., Laureti, S., Grenbäck, E., Hulting, A.L., Casucci, G., et al. (1995) High Diagnostic Accuracy for Idiopathic Addison’s Disease with a Sensitive Radiobinding Assay for Autoantibodies against Recombinant Human 21-Hydroxylase. The Journal of Clinical Endocrinology & Metabolism, 80, 2752-2755. https://doi.org/10.1210/jcem.80.9.7673419
[11]
Song, Y.H., Connor, E.L., Muir, A., She, J.X., Zorovich, B., Derovanesian, D., et al. (1994) Autoantibody Epitope Mapping of the 21-Hydroxylase Antigen in Autoimmune Addison’s Disease. The Journal of Clinical Endocrinology & Metabolism, 78, 1108-1112. https://doi.org/10.1210/jcem.78.5.7513715
[12]
Boe, A., Bredholt, G., Knappskog, P., Hjelmervik, T., Mellgren, G., Winqvist, O., et al. (2004) Autoantibodies against 21-Hydroxylase and Side-Chain Cleavage Enzyme in Autoimmune Addison’s Disease Are Mainly Immunoglobulin G1. European Journal of Endocrinology, 150, 49-56. https://doi.org/10.1530/eje.0.1500049
[13]
Michels, A. and Michels, N. (2014) Addison Disease: Early Detection and Treatment Principles. American Family Physician, 89, 563-568.